IRF4 in Multiple Myeloma —biology, disease and therapeutic target

Multiple Myeloma (MM) is an aggressive and incurable cancer characterized by the clonal proliferation of bone marrow plasma cells. MM diagnosis follows the appearance of end-organ damage known as the CRAB criteria (increased calcium level, renal dysfunction, anaemia, and destructive bone lesions) but can also be diagnosed in presence of at least one myeloma defining event or MED (bone marrow plasma cells greater than or equal to 60%; serum free light chain ratio greater than or equal to 100 provided involved FLC level is at least 100  mg/L; more than one focal lesion on magnetic resonance imaging that is at least 5 mm or greater in size) [1].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research